Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OmniAb, Inc.OABI · Entity 5294 | Chief Legal Officer | April 07, 2026 | April 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OmniAb, Inc.
Report date April 07, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 399,085 |
Ending reported balance
After 2026-04-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-07 · Exercise / conversion · Acquired 13,542 · Balance 406,242 F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-04-07 · Sale · Disposed 7,157 · Balance 399,085 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 111,042 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Exercise / conversion · Disposed 13,542 · Balance 111,042 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LIGAND PHARMACEUTICALS INC
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,825 |
Reported balance
After 2022-11-01 transaction · row 1
1 source rowRow 1 · 2022-11-01 · Disposition to issuer · Disposed 11,944 · Balance 23,825 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.68 · Expires 2032-05-05 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 20,126 · Balance 0 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
OmniAb Operations, Inc.
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,587 |
Reported balance
After 2022-11-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-01 · Grant · Acquired 15,409 · Balance 52,587 F1: Includes 9,564 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F2: Includes 26,789 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 52,587 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05 | Direct | 35,810 |
Reported balance
After 2022-11-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-01 · Grant · Acquired 35,810 · Balance 35,810 F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-01 · Disposition to issuer · Disposed 35,810 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2025-02-10 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-01 · Disposition to issuer · Disposed 1,701 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.21 · Expires 2026-02-11 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-01 · Disposition to issuer · Disposed 3,627 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $56.41 · Expires 2027-02-24 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-11-01 · Disposition to issuer · Disposed 5,966 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $89.36 · Expires 2028-03-02 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-11-01 · Disposition to issuer · Disposed 8,117 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $66.30 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-11-01 · Disposition to issuer · Disposed 12,797 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $53.77 · Expires 2030-02-13 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-11-01 · Disposition to issuer · Disposed 15,043 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $99.75 · Expires 2031-02-03 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-11-01 · Disposition to issuer · Disposed 6,076 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 9,564 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.
F2: Includes 26,789 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9.
F3: Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022.
F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.
F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
F6: The stock option is fully vested and exercisable.
F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter.
F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter.
F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2020 Filed Jun 5, 2020 20:07 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 11,146 | $118.59 | $1,321,775.16 |
DisclosureSEC source: 0000886163-20-000063 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,877 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.27 to $118.935, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 22:07 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 367 | $97.23 | $35,683.41 |
DisclosureSEC source: 0000886163-20-000015 · edgardoc.xml · nonDerivative · entry 4 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,023 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 22:07 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 207 | $97.23 | $20,126.61 |
DisclosureSEC source: 0000886163-20-000015 · edgardoc.xml · nonDerivative · entry 3 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,390 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 03/02/2018. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 22:07 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 307 | $97.23 | $29,849.61 |
DisclosureSEC source: 0000886163-20-000015 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,597 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/24/2017. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:07 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 17,220 | $0.00 Strike: $95.68 | $0.00 |
DisclosureSEC source: 0000886163-20-000015 · edgardoc.xml · derivative · entry 5 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,220 Underlying: Common Stock · 17,220 shares Expires 2030-02-13 F4 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/13/2020. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:07 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 3,835 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-20-000015 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,904 Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 19:01 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 546 | $105.87 | $57,805.02 |
DisclosureSEC source: 0000886163-19-000208 · edgardoc.xml · nonDerivative · entry 4 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,069 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 19:01 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,335 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000208 · edgardoc.xml · nonDerivative · entry 3 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,615 F3 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/30/2018 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2019. On December 20, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 19:01 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 585 | $105.87 | $61,933.95 |
DisclosureSEC source: 0000886163-19-000208 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,280 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 19:01 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,693 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000208 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,865 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 03/29/2017 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2019. On December 20, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 21:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 424 | $0.00 Strike: $85.79 | $0.00 |
DisclosureSEC source: 0000886163-19-000144 · edgardoc.xml · derivative · entry 4 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,153 Underlying: Common Stock · 424 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/11/16. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 21:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 669 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0000886163-19-000144 · edgardoc.xml · derivative · entry 3 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,948 Underlying: Common Stock · 669 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/10/15. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 21:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 424 | $85.79 | $36,374.96 |
DisclosureSEC source: 0000886163-19-000144 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 21:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 669 | $56.26 | $37,637.94 |
DisclosureSEC source: 0000886163-19-000144 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2019 Filed Jul 3, 2019 01:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 182 | $97.03 | $17,659.01 |
DisclosureSEC source: 0000886163-19-000121 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,079 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 14,649 | $0.00 Strike: $117.97 | $0.00 |
DisclosureSEC source: 0000886163-19-000034 · edgardoc.xml · derivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,649 Underlying: Common Stock · 14,649 shares Expires 2029-03-02 F1 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/11/19. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 3,202 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000034 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,897 Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,412 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000019 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,695 F2 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 03/29/2017 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2018. On January 23, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000019 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,283 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 02/11/2016 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2018. On January 23, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 14:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,931 | $0.00 Strike: $74.42 | $0.00 |
DisclosureSEC source: 0000886163-19-000005 · edgardoc.xml · derivative · entry 6 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,931 shares Expires 2024-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/12/14. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 14:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 675 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0000886163-19-000005 · edgardoc.xml · derivative · entry 5 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,617 Underlying: Common Stock · 675 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/10/15. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 14:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 244 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0000886163-19-000005 · edgardoc.xml · derivative · entry 4 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 244 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 14:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 675 | $56.26 | $37,975.50 |
DisclosureSEC source: 0000886163-19-000005 · edgardoc.xml · nonDerivative · entry 3 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 14:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,931 | $74.42 | $143,705.02 |
DisclosureSEC source: 0000886163-19-000005 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 14:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 244 | $21.92 | $5,348.48 |
DisclosureSEC source: 0000886163-19-000005 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 00:58 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,400 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0000886163-18-000172 · edgardoc.xml · derivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244 Underlying: Common Stock · 3,400 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 00:58 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 3,400 | $21.92 | $74,528.00 |
DisclosureSEC source: 0000886163-18-000172 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2018 Filed Oct 25, 2018 21:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,688 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000886163-18-000154 · edgardoc.xml · derivative · entry 4 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,688 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/09/12. Read SEC document |
| October 24, 2018 Filed Oct 25, 2018 21:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,212 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0000886163-18-000154 · edgardoc.xml · derivative · entry 3 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,644 Underlying: Common Stock · 1,212 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document |
| October 24, 2018 Filed Oct 25, 2018 21:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,212 | $21.92 | $26,567.04 |
DisclosureSEC source: 0000886163-18-000154 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2018 Filed Oct 25, 2018 21:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,688 | $14.47 | $38,895.36 |
DisclosureSEC source: 0000886163-18-000154 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2018 Filed Oct 12, 2018 22:52 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000886163-18-000150 · edgardoc.xml · derivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,688 Underlying: Common Stock · 2,000 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/09/12. Read SEC document |
| October 11, 2018 Filed Oct 12, 2018 22:52 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,000 | $14.47 | $28,940.00 |
DisclosureSEC source: 0000886163-18-000150 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 22:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,813 | $0.00 Strike: $100.38 | $0.00 |
DisclosureSEC source: 0000886163-18-000135 · edgardoc.xml · derivative · entry 3 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,830 Underlying: Common Stock · 2,813 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1. F3 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/24/2017. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 22:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,813 | $250.69 | $705,181.41 |
DisclosureSEC source: 0000886163-18-000135 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,763 F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.43 to $254.65, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 22:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,813 | $100.38 | $282,368.94 |
DisclosureSEC source: 0000886163-18-000135 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 00:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 469 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0000886163-18-000132 · edgardoc.xml · derivative · entry 9 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 469 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1. F6 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/15/13. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 00:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,886 | $0.00 Strike: $85.79 | $0.00 |
DisclosureSEC source: 0000886163-18-000132 · edgardoc.xml · derivative · entry 8 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,577 Underlying: Common Stock · 5,886 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1. F5 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/11/16. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 00:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,985 | $0.00 Strike: $74.42 | $0.00 |
DisclosureSEC source: 0000886163-18-000132 · edgardoc.xml · derivative · entry 7 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,931 Underlying: Common Stock · 5,985 shares Expires 2024-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1. F4 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/12/14. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 00:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,077 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0000886163-18-000132 · edgardoc.xml · derivative · entry 6 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,292 Underlying: Common Stock · 7,077 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1. F3 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/10/15. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 00:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 19,417 | $254.99 | $4,951,065.10 |
DisclosureSEC source: 0000886163-18-000132 · edgardoc.xml · nonDerivative · entry 5 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,763 F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.85 to $256.59, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 00:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 5,886 | $85.79 | $504,959.94 |
DisclosureSEC source: 0000886163-18-000132 · edgardoc.xml · nonDerivative · entry 4 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 00:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 7,077 | $56.26 | $398,152.02 |
DisclosureSEC source: 0000886163-18-000132 · edgardoc.xml · nonDerivative · entry 3 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 00:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 5,985 | $74.42 | $445,403.70 |
DisclosureSEC source: 0000886163-18-000132 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 00:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 469 | $21.92 | $10,280.48 |
DisclosureSEC source: 0000886163-18-000132 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 19:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 180 | $117.84 | $21,210.39 |
DisclosureSEC source: 0000886163-18-000088 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,763 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document |
| March 06, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 392 | $165.87 | $65,021.04 |
DisclosureSEC source: 0000886163-18-000041 · edgardoc.xml · nonDerivative · entry 3 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,583 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| March 06, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,136 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-18-000041 · edgardoc.xml · nonDerivative · entry 2 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,975 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer?s common stock. The PSUs were originally granted on 02/11/2016 and were eligible to vest based on the Issuer?s achievement of certain performance objectives during the two-year performance period ending December 31, 2017. On March 05, 2018, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer?s achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 9,292 | $0.00 Strike: $159.01 | $0.00 |
DisclosureSEC source: 0000886163-18-000041 · edgardoc.xml · derivative · entry 4 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,292 Underlying: Common Stock · 9,292 shares Expires 2028-03-02 F3 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 03/02/18. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,780 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-18-000041 · edgardoc.xml · nonDerivative · entry 1 Berkman Charles S · CIK 0001392266 · SVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,839 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.